MDxHealth has achieved a number of significant milestones in the 1H/2017. The company continues to gain traction for its products amongst key US healthcare providers. It has expanded its product offering through the launches of AssureMDx for bladder and the IVD version of SelectMDx for prostate cancer; an agreement is already in place with a major laboratory service provider to supply the IVD test in Germany. After a positive first four month trading statement in May, we are optimistic that first half numbers due next week (31/08) will indicate MDxH is on track for its 55% - 75% product revenues growth guidance. We reiterate both our OUTPERFORM recommendation and €6.50 target price.
